Trials / Completed
CompletedNCT00509704
Influence of Sutent on Tumor Vascularization and Necrosis in Patients With Renal Cell Carcinoma
Pilot Study on the Influence of Sutent on Tumor Vascularization and Necrosis in Patients With Renal Cell Carcinoma
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 10 (estimated)
- Sponsor
- Radboud University Medical Center · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of the study is to assess the effect of Sunitinib on tumor vascularization and necrosis in patients with metastatic renal cell cancer.
Detailed description
Sutent is an angiogenesis inhibitor used in the treatment of renal cell cancer. Very often tumor necrosis is seen after the start of the treatment. It is unknown after how many days this effect starts. In patients with renal cell cancer with metastases, who will be treated with Sutent, 3 MRIs will be made. Kep, R2\*, b-coefficient (perfusion, hypoxia, blood volume and necrosis) will be measured.
Conditions
Timeline
- Start date
- 2008-10-01
- Completion
- 2010-05-01
- First posted
- 2007-07-31
- Last updated
- 2010-11-09
Locations
1 site across 1 country: Netherlands
Source: ClinicalTrials.gov record NCT00509704. Inclusion in this directory is not an endorsement.